secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001285550-24-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M
--------------------------------------------------------------------------------

- Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.
- Biologics & drug delivery revenue $13.6M in 2023, +49% YoY; gross margin 57% (down from 66%).
- Cash & equivalents $23.1M at Dec 31; Q4 cash burn reduced to $1.2M.
- Reaffirmed 2024 revenue guidance $28M-$32M; early 2024 milestones include 6 new hospitals, FDA clearance, ~$15M equity offering.
- Operating expenses $36.1M in 2023 (up from $29.9M), driven by higher headcount and share-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/clpt-20240312.htm
  HTML page:      https://secwatch.observer/filing/0001285550-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer